Chart Of The Day: Will Regeneron Receive A Boost From Trump's 'Miracle Cure?'
Investing.com | Oct 08, 2020 09:44AM ET
Two recent, fast-changing market themes—on-again/off-again hopes of additional fiscal stimulus and US President Donald Trump's coronavirus diagnosis—have thrown markets into a tizzy.
Though the stimulus drama has yet to be resolved, the president was released from the hospital earlier this week and is back at the White House, talking up his 'miracle cure' as “a blessing from God.” The 'cure' he's been referring to is the result of a number of as-yet-unproven theraputics. including an antibody cocktail that drugmaker Regeneron Pharmaceuticals (NASDAQ:REGN) has been developing.
In a video released yesterday, Trump said he planned to make the drug free to anyone who needs it. Of course, he didn't address the fact that it hasn't yet received government approval, though Regeneron did announce Wednesday it had submitted a request to the Food and Drug Administration (FDA) for an emergency use authorization.
The president's focus on Regeneron sent its slumping stock, which closed yesterday at $591.69, into a rebound, boosting shares in afterhours trade by almost $21, or 3.5%.
So is the stock a buy? Over the longer term we can't know. But it could prove to be a good momentum trade in the shorter term.
If the stock opens later today at the current pre-market price of $623 at time of writing, it will have blown two consecutive bearish patterns—a H&S top and a bearish flag. And if no other sudden, crazy headlines about the drug hit the wires, it will have flipped direction, setting it up for a continued advance, with the next major resistance at the July 20 all-time high of $664.64.
This would provide room for another $40 run up, a gain of 6%.
h2 Trading Strategies/h2Conservative traders would wait for a return to that high, followed by a pullback to join the continued uptrend.
Moderate traders would wait for a pullback to the broken flag before risking a long position.
Aggressive traders would enter a long now, provided they understand and accept the risks. Careful planning would limit risk while allowing gains to run. Here’s an example:
Trade Sample
- Entry: $623
- Stop-Loss: $613
- Loss: $10
- Target: $663
- Reward: $40
- Risk:Reward Ratio: 1:4
Author's Note: This is a trade sample, not the complete analysis. That’s in the body of the post. Even if the analysis is right, and we’re not saying it is, the trade might still fail. Your timing, budget and temperament will contribute to its success or failure. That’s why it’s imperative to keep your trading strategies consistent, to develop statistical results and to determine what works for you.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.